Solitaire-Iv: Results Of A Phase 3 Iv To Oral Trial In Adults With Community-Acquired Bacterial Pneumonia Comparing Solithromycin To Moxifloxacin

被引：0
|
作者：
File, T. M., Jr. [1 ]
Rewerska, B. [2 ]
Tanaseanu, C. M. [3 ]
Mihailovic-Vucinic, V. [4 ]
Gonong, J. R. [5 ]
Jamieson, B. D. [6 ]
Taylor, D. [6 ]
Sheets, A. [6 ]
Keedy, K. [6 ]
Oldach, D. W. [6 ]
Fernandes, P. [6 ]
机构：
[1] Summa Hlth Syst, Akron, OH USA
[2] Diamond Clin, Krakow, Poland
[3] St Pantelimon Emergency Clin Hosp, Bucharest, Romania
[4] Clin Ctr Serbia, Belgrade, Serbia
[5] Lung Ctr Philippines, Manila, Philippines
[6] Cempra Inc, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2116
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia
    File, Thomas M., Jr.
    Rewerska, Barbara
    Vucinic-Mihailovic, Violeta
    Gonong, Joven Roque V.
    Das, Anita F.
    Keedy, Kara
    Taylor, David
    Sheets, Amanda
    Fernandes, Prabhavathi
    Oldach, David
    Jamieson, Brian D.
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (08) : 1007 - 1016
  • [2] Oral Solithromycin Versus Oral Moxifloxacin For Treatment Of Adult Community-Acquired Bacterial Pneumonia (cabp): Results Of The Global Phase-3 Trial Solitaire-Oral
    Oldach, D. W.
    Barrera, C. M.
    Metev, H.
    Dvoretskiy, L. I.
    Mykietiuk, A.
    Mitha, I.
    De Salvo, M. C.
    Tanaseanu, C. M.
    Szabo, P.
    Clark, K.
    Jamieson, B.
    Das, A.
    Keedy, K.
    Fernandes, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [3] Moxifloxacin (IV/PO) for patients with severe community-acquired pneumonia
    Grossman, C
    Choudhri, S
    Haverstock, D
    Jackson, P
    Church, D
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1109 - 1109
  • [4] Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia
    Torres, Antoni
    Garrity-Ryan, Lynne
    Kirsch, Courtney
    Steenbergen, Judith N.
    Eckburg, Paul B.
    Das, Anita F.
    Curran, Marla
    Manley, Amy
    Tzanis, Evan
    McGovern, Paul C.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 104 : 501 - 509
  • [5] DIAGNOSIS AND OUTCOMES IN PATIENTS WITH ATYPICAL PATHOGENS IN A PHASE-3 COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA TRIAL COMPARING DELAFLOXACIN TO MOXIFLOXACIN
    Cammarata, Sue
    Keedy, Kara
    Sheets, Amanda
    Nenninger, Ashley
    McCurdy, Sandra
    Quintas, Megan
    Lawrence, Laura
    Li, Yang
    CHEST, 2019, 156 (04) : 422A - 423A
  • [6] Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia
    Lode, H
    Grossman, C
    Choudhri, S
    Haverstock, D
    McGivern, J
    Herman-Gnjidic, Z
    Church, D
    RESPIRATORY MEDICINE, 2003, 97 (10) : 1134 - 1142
  • [7] Nabriva Therapeutics Announces Positive Topline Results From Global Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
    不详
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (11) : I - II
  • [8] Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)
    Barrera, Carlos M.
    Mykietiuk, Analia
    Metev, Hristo
    Nitu, Mimi Floarea
    Karimjee, Najumuddin
    Doreski, Pablo Alexis
    Mitha, Ismail
    Tanaseanu, Cristina Mihaela
    Molina, Joseph McDermott
    Antonovsky, Yuri
    Van Rensburg, Dirkie Johanna
    Rowe, Brian H.
    Flores-Figueroa, Jose
    Rewerska, Barbara
    Clark, Kay
    Keedy, Kara
    Sheets, Amanda
    Scott, Drusilla
    Horwith, Gary
    Das, Anita F.
    Jamieson, Brian
    Fernandes, Prabhavathi
    Oldach, David
    LANCET INFECTIOUS DISEASES, 2016, 16 (04): : 421 - 430
  • [9] Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
    H Lode
    S Choudhri
    D Haverstock
    P Jackson
    D Church
    Critical Care, 6 (Suppl 1):
  • [10] Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
    McCurdy, Sandra
    Keedy, Kara
    Lawrence, Laura
    Nenninger, Ashley
    Sheets, Amanda
    Quintas, Megan
    Cammarata, Sue
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
12345